Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -445.85% is 84% above its 5-year average of -2831.38%, near the high end of its 5-year range (-107175.00%–58.36%).
86.92% above its 12-month average of -3407.49%.
Reported quarterly EBITDA margin; no daily interpolation. Q2 FY2026 (2026-06-30): -2255.56%.
EBITDA MARGIN
-445.85%
EBITDA MARGIN AVG TTM
-3407.49%
EBITDA MARGIN AVG 3Y
-2429.03%
EBITDA MARGIN AVG 5Y
-2831.38%
EBITDA MARGIN AVG 10Y
-2012.92%
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+86.92%
CURRENT VS 3Y AVG
+81.64%
CURRENT VS 5Y AVG
+84.25%
CURRENT VS 10Y AVG
+77.85%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
CollPlant Biotechnologies Ltd.
Market Cap
$4.42M
EBITDA Margin
-445.85%
TTM Avg
-3407.49%
3Y Avg
-2429.03%
5Y Avg
-2831.38%
Market Cap
$4.41M
EBITDA Margin
-2411.68%
TTM Avg
-15920.55%
3Y Avg
-15920.55%
5Y Avg
-10610.40%
Market Cap
$4.32M
EBITDA Margin
-159.06%
TTM Avg
-237.19%
3Y Avg
-222.87%
5Y Avg
-159.05%
Market Cap
$4.18M
EBITDA Margin
-1456.00%
TTM Avg
-1456.00%
3Y Avg
-1456.00%
5Y Avg
-1456.00%
Market Cap
$4.79M
EBITDA Margin
-1127.44%
TTM Avg
-14514.89%
3Y Avg
-11694.21%
5Y Avg
-11694.21%
Market Cap
$3.94M
EBITDA Margin
-890.82%
TTM Avg
-527.81%
3Y Avg
-554.45%
5Y Avg
-445.87%
Market Cap
$4.96M
EBITDA Margin
-8.85%
TTM Avg
9.13%
3Y Avg
18.32%
5Y Avg
18.32%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| CollPlant Biotechnologies Ltd. (CLGN) | $4.42M | -445.85% | -3407.49% | -2429.03% | -2831.38% |
| Ernexa Therapeutics Inc. (ERNA)vs › | $4.41M | -2411.68% | -15920.55% | -15920.55% | -10610.40% |
| Dermata Therapeutics, Inc. (DRMA)vs › | $4.46M | N/A | N/A | N/A | N/A |
| 20/20 Biolabs Inc. (AIDX)vs › | $4.32M | -159.06% | -237.19% | -222.87% | -159.05% |
| GRI Bio, Inc. (GRI)vs › | $4.18M | -1456.00% | -1456.00% | -1456.00% | -1456.00% |
| Bio Green Med Solution, Inc. (BGMS)vs › | $4.79M | -1127.44% | -14514.89% | -11694.21% | -11694.21% |
| CalciMedica, Inc. (CALC)vs › | $4.85M | N/A | N/A | N/A | N/A |
| Aptevo Therapeutics Inc. (APVO)vs › | $3.94M | -890.82% | -527.81% | -554.45% | -445.87% |
| Basel Medical Group Ltd Ordinary Shares (BMGL)vs › | $4.96M | -8.85% | 9.13% | 18.32% | 18.32% |
| Gelteq Limited Ordinary Shares (GELS)vs › | $4.99M | -2579.35% | -2579.35% | -2089.74% | -2089.74% |
Gross Margin
26.3%
EBITDA Margin
-445.9%
Operating Margin
-484.3%
Net Margin
-3934.9%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2026-06-30 | -2255.56% |
| 2026-03-31 | -3979.45% |
| 2025-12-31 | -4890.00% |
| 2025-09-30 | -4264.94% |
| 2025-06-30 | -1647.49% |
| 2025-03-31 | -68.32% |
| 2024-12-31 | -2275.61% |
| 2024-09-30 | -107175.00% |
| 2024-06-30 | -1664.66% |
| 2024-03-31 | -4131.63% |
| 2023-12-31 | -1600.00% |
| 2023-09-30 | -10069.77% |
| 2023-06-30 | 58.36% |
| 2023-03-31 | -748.04% |
| 2022-12-31 | -7555.17% |
| 2022-09-30 | -3841.28% |
| 2022-06-30 | -5945.45% |
| 2022-03-31 | -5345.45% |
| 2021-12-31 | -1154.84% |
| 2021-09-30 | -2069.29% |
| 2021-06-30 | -417.37% |
| 2021-03-31 | 70.34% |
| 2020-12-31 | -457.27% |
| 2020-09-30 | 21.72% |
| 2020-06-30 | -212.64% |
| 2020-03-31 | -253.37% |
| 2019-09-30 | -236.38% |
| 2019-06-30 | -268.98% |
| 2019-03-31 | -245.62% |
| 2018-12-31 | 18.42% |
| 2018-09-30 | -633.64% |
| 2018-06-30 | -723.50% |
| 2018-03-31 | -888.45% |
| 2017-12-31 | -627.22% |
| 2017-09-30 | -1331.95% |
| 2017-06-30 | -2705.01% |
| 2017-03-31 | -1896.44% |
| 2016-12-31 | -3197.78% |
| 2016-09-30 | -7114.19% |
